Two unsuccessful clinical trials on endometriosis and a few lessons learned

Gynecologic and Obstetric Investigation

Volumn 64, Issue 1, 2007, Pages 24-35

  Guo, Sun Wei ^a   Olive, David L ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Clinical trials, endometriosis; Endometriosis; Estrogen receptor; Estrogen receptor modulators, selective; Fulvestrant; Raloxifene

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 2 (3 FLUORO 4 HYDROXYPHENYL) 7 VINYL 5 BENZOXAZOLOL; ANTIESTROGEN; AROMATASE INHIBITOR; CETRORELIX; CYCLOOXYGENASE 2; DR 2001; ESTROGEN RECEPTOR; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FULVESTRANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUPRORELIN; NAFARELIN; NORETHISTERONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; RALOXIFENE; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SHT 00660AA; SHT 04268H; SOMATOMEDIN BINDING PROTEIN 3; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCREENING; UTERUS MYOMA;

ADULT; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIOSIS; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEEDS ASSESSMENT; RALOXIFENE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY; TREATMENT FAILURE;

EID: 34347348174     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098413     Document Type: Review

References (137)

1. Gurates B, Bulun SE: Endometriosis: the ultimate hormonal disease. Semin Reprod Med 2003;21:125-134.
2. Kitawaki J, Kado N, Ishihara H, et al: Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002;83:149-155.
3. Mahmood TA, Templeton A: Prevalence and genesis of endometriosis. Hum Reprod 1991;6:544-549.
4. Olive DL, Schwartz LB: Endometriosis. N Engl J Med 1993;328:1759-1769.
5. Farquhar CM: Extracts from the 'clinical evidence'. Endometriosis. BMJ 2000;320:1449-1452.
6. Wheeler JM, Malinak LR: Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 1983;146:247-253.
7. Namnoum AB, Hickman TN, Goodman SB, et al: Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril 1995;64:898-902.
8. Olive DL, Pritts EA: Treatment of endometriosis. N Engl J Med 2001;345:266-275.
9. Lessey BA: Medical management of endometriosis and infertility. Fertil Steril 2000;73:1089-1096.
10. Valle RF, Sciarra JJ: Endometriosis: treatment strategies. Ann NY Acad Sci 2003;997:229-239.
11. Moore J, Kennedy S, Prentice A: Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2000, p CD001019.
12. McLaren J, Prentice A, Charnock-Jones DS, et al: Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996;98:482-489.
13. Prentice A, Deary AJ, Bland E: Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000;CD002122.
14. Prentice A, Deary AJ, Goldbeck-Wood S, et al: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2000;CD000346.
15. Selak V, Farquhar C, Prentice A, Singla A, et al: Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001;CD000068.
16. Waller KG, Shaw RW: Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59:511-515.
17. Nothnick WB, D'Hooghe TM: Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimes. Gynecol Obstet Invest 2003;55:189-198.
18. Fedele L, Berlanda N: Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2004;9:167-177.
19. Zarin DA, Tse T, Ide NC: Trial Registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 2005;353:2779-2787.
20. Levesque C, Merand Y, Dufour JM, et al: Synthesis and biological activity of new halosteroidal antiestrogens. J Med Chem 1991;34:1624-1630.
21. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873.
22. Nique F, Van de Velde P, Bremaud J, et al: 11 beta-Amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Mol Biol 1994;50:21-29.
23. Wakeling AE: Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 1995;49:1545-1549.
24. Pink JJ, Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321-2330.
25. Dauvois S, White R, Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-1388.
26. Parker MG: Action of 'pure' antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131-137.
27. Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 2000;89:817-825.
28. Dukes M, Miller D, Wakeling AE, Waterton JC: Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992;135:239-247.
29. Dukes M, Waterton JC, Wakeling AE: Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 1993;138:203-210.
30. Thomas EJ, Walton PL, Thomas NM, Dowsett M: The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 1994;9:1991-1996.
31. Dowsett M, Howell R, Salter J, et al: Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Hum Reprod 1995;10:262-267.
32. Donnez J, Hervais Vivancos B, Kudela M, et al: A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril 2003;79:1380-1389.
33. Osborne CK, Pippen J, Jones SE, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
34. Evans A, Vollenhoven B, Healy D: Modern antioestrogens and the coming revolution in women's health care. Aust NZ J Obstet Gynaecol 1999;39:334-340.
35. Johnston SR: Fulvestrant (AstraZeneca). Curr Opin Investig Drugs 2002;3:305-312.
36. Wu Y, Guo SW: Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 2006;62:193-205.
37. Glasebrook AL, Phillips DL, Sluka JP: Multiple binding sites for the antiestrogen raloxifene (LY156758). J Miner Res 1993;8:S268.
38. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
39. Black LJ, Sato M, Rowley ER, et al: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-69.
40. Sato M, Kim J, Short LL, et al: Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995;272:1252-1259.
41. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983;329:1031-1036.
42. Fuchs-Young R, Glasebrook AL, Short LL, et al: Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995;761:355-360.
43. Sato M, Rippy MK, Bryant HU: Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-912.
44. Ashby J, Odum J, Foster JR: Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 1997;25:226-231.
45. Baker VL, Draper M, Paul S, et al: Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998;83:6-13.
46. Swisher DK, Tague RM, Seyler DE: Effects of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug Dev Res 1995;36:43-45.
47. Fanning P, Kühl T, Lee R, Pearson S, Wincek T, Pliego J: Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey, Macaca mulatta; in Kuehl TJ (ed): Bunkley Day Proceedings. Temple, Texas A&M University Health Science Center, 1996, pp 51-61.
48. Yao Z, Shen X, Capodanno I, et al: Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg 2005;18:177-183.
49. Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, Winkel C, Nieman LK: Raloxifene accelerates the return of chronic pelvic pain from endometriosis after surgical treatment. Eur J Gynecol Reprod Biol 2005;123(suppl 1):S22.
50. Rothman KJ, Greenland S: Causation and causal inference; in Rothman KJ, Greenland S (eds): Modern Epidemiology. Philadelphia, Lippincott-Raven Press, 1998, pp 7-28.
51. Smith CL, O'Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45-71.
52. Zeitoun KM, Bulun SE: Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-969.
53. Bulun SE, Zeitoun KM, Takayama K, Sasano H: Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update 2000;6:413-418.
54. Bulun SE, Lin Z, Imir G, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-383.
55. Tamaya T, Motoyama T, Ohono Y, et al: Steroid receptor levels and histology of endometriosis and adenomyosis. Fertil Steril 1979;31:396-400.
56. Janne O, Kauppila A, Kokko E, et al: Estrogen and progestin receptors in endometriosis lesions: comparison with endometrial tissue. Am J Obstet Gynecol 1981;141:562-566.
57. Gould SF, Shannon JM, Cunha GR: Nuclear estrogen binding sites in human endometriosis. Fertil Steril 1983;39:520-524.
58. Bergqvist A, Jeppsson S, Ljungberg O: Histochemical demonstration of estrogen and progesterone binding in endometriotic tissue and in uterine endometrium: a comparative study. J Histochem Cytochem 1985;33:155-161.
59. Bergqvist A, Ljungberg O, Skoog L: Immunohistochemical analysis of oestrogen and progesterone receptors in endometriotic tissue and endometrium. Hum Reprod 1993;8:1915-1922.
60. Lessey BA, Metzger DA, Haney AF, McCarty KS Jr: Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 1989;51:409-415.
61. Bur ME, Greene GL, Press MF: Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues. Int J Gynecol Pathol 1987;6:140-151.
62. Lyndrup J, Thorpe S, Glenthoj A, et al: Altered progesterone/estrogen receptor ratios in endometriosis. A comparative study of steroid receptors and morphology in endometriosis and endometrium. Acta Obstet Gynecol Scand 1987;66:625-629.
63. Prentice A, Randall BJ, Weddell A, et al: Ovarian steroid receptor expression in endometriosis and in two potential parent epithelia: endometrium and peritoneal mesothelium. Hum Reprod 1992;7:1318-1325.
64. Jones RK, Bulmer JN, Searle RF: Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod 1995;10:3272-3279.
65. Misao R, Fujimoto J, Nakanishi Y, Tamaya T: Expression of estrogen and progesterone receptors and their mRNAs in ovarian endometriosis. Gynecol Endocrinol 1996;10:303-310.
66. Matsuzaki S, Fukaya T, Suzuki T, et al: Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 1999;5:559-564.
67. Matsuzaki S, Uehara S, Murakami T, et al: Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real-time reverse transcription-polymerase chain reaction assay. Fertil Steril 2000;74:753-759.
68. Matsuzaki S, Fukaya T, Uehara S, et al: Characterization of messenger RNA expression of estrogen receptor-alpha and -beta in patients with ovarian endometriosis. Fertil Steril 2000;73:1219-1225.
69. Brandenberger AW, Lebovic DI, Tee MK, et al: Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod 1999;5:651-655.
70. Fujimoto J, Hirose R, Sakaguchi H, Tamaya T: Expression of oestrogen receptor-alpha and -beta in ovarian endometriomata. Mol Hum Reprod 1999;5:742-747.
71. Fazleabas AT, Brudney A, Chai D, et al: Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril 2003;80(suppl 2):820-827.
72. Fujishita A, Nakane PK, Koji T, et al: Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril 1997;67:856-864.
73. Hudelist G, Keckstein J, Czerwenka K, et al: Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril 2005;84(suppl 2):1249-1256.
74. Marshburn PB, Zhang J, Bahrani-Mostafavi Z, et al: Estrogen receptor-alpha messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle. Am J Obstet Gynecol 2004;191:626-633; discussion 633-634.
75. Rey JM, Pujol P, Dechaud H, et al: Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients. Mol Hum Reprod 1998;4:641-647.
76. Cooke PS, Buchanan DL, Young P, et al: Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997;94:6535-6540.
77. Cunha GR, Cooke PS, Kurita T: Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67:417-434.
78. Nadal A, Ropero AB, Fuentes E, Soria B: The plasma membrane estrogen receptor: nuclear or unclear? Trends Pharmacol Sci 2001;22:597-599.
79. O'Lone R, Frith MC, Karlsson EK, Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004;18:1859-1875.
80. Story L, Kennedy S: Animal studies in endometriosis: a review. ILAR J 2004;45:132-138.
81. Schenken RS, Asch RH: Surgical induction of endometriosis in the rabbit: effects on fertility and concentrations of peritoneal fluid prostaglandins. Fertil Steril 1980;34:581-587.
82. Vernon MW, Wilson EA: Studies on the surgical induction of endometriosis in the rat. Fertil Steril 1985;44:684-694.
83. Steinleitner A, Lambert H, Suarez M, et al: Periovulatory calcium channel blockade enhances reproductive performance in an animal model for endometriosis-associated subfertility. Am J Obstet Gynecol 1991;164:949-952.
84. Zamah NM, Dodson MG, Stephens LC, et al: Transplantation of normal and ectopic human endometrial tissue into athymic nude mice. Am J Obstet Gynecol 1984;149:591-597.
85. Awwad JT, Sayegh RA, Tao XJ, et al: The SCID mouse: an experimental model for endometriosis. Hum Reprod 1999;14:3107-3111.
86. D'Hooghe TM, Bambra CS, Raeymaekers BM, Hill JA: Pelvic inflammation induced by diagnostic laparoscopy in baboons. Fertil Steril 1999;72:1134-1141.
87. Yano S, Ikegami Y, Nakao K: Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung 1996;46:192-195.
88. Kudoh M, Susaki Y, Ideyama Y, et al: Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol 1997;63:75-80.
89. Takayama K, Zeitoun K, Gunby RT, et al: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998;69:709-713.
90. Anaf V, Simon P, El Nakadi I, et al: Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000;15:1744-1750.
91. Gruppo Italiano per lo Studio dell'Endometriosi: Relationship between stage, site and morphological characteristics of pelvic endometriosis and pain. Hum Reprod 2001;16:2668-2671.
92. Szendei G, Hernadi Z, Devenyi N, Csapo Z: Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol 2005;21:93-100.
93. Vercellini P, Fedele L, Aimi G, et al: Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current classification system. Hum Reprod 2006;21:2679-2685.
94. Johnson JI, Decker S, Zaharevitz D, et al: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-1431.
95. Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
96. Vinatier D, Cosson M, Dufour P: Is endometriosis an endometrial disease? Eur J Obstet Gynecol Reprod Biol 2000;91:113-125.
97. Vinatier D, Orazi G, Cosson M, Dufour P: Theories of endometriosis. Eur J Obstet Gynecol Reprod Biol 2001;96:21-34.
98. Beliard A, Noel A, Foidart JM: Reduction of apoptosis and proliferation in endometriosis. Fertil Steril 2004;82:80-85.
99. Wu Y, Kajdacsy-Balla A, Strawn E, et al: Transcriptional characterizations of differences between eutopic and ectopic endometrium. Endocrinology 2006;147:232-246.
100. Razzi S, Fava A, Sartini A, et al: Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004;111:182-184.
101. Shippen ER, West WJ Jr: Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81:1395-1398.
102. Ailawadi RK, Jobanputra S, Kataria M, et al: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-296.
103. Noble LS, Simpson ER, Johns A, Bulun SE: Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996;81:174-179.
104. Noble LS, Takayama K, Zeitoun KM, et al: Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-606.
105. McClelland RA, Gee JM, Francis AB, et al: Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 1996;32A:413-416.
106. McClelland RA, Manning DL, Gee JM, et al: Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 1996;41:31-41.
107. Frasor J, Stossi F, Danes JM, et al: Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64:1522-1533.
108. Krikun G, Mor G, Alvero A, et al: A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology 2004;145:2291-2296.
109. Barbier CS, Becker KA, Troester MA, Kaufman DG: Expression of exogenous human telomerase in cultures of endometrial stromal cells does not alter their hormone responsiveness. Biol Reprod 2005;73:106-114.
110. Kyo S, Nakamura M, Kiyono T, et al: Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003;163:2259-2269.
111. Hombach-Klonisch S, Kehlen A, Fowler PA, et al: Regulation of functional steroid receptors and ligand-induced responses in telomerase-immortalized human endometrial epithelial cells. J Mol Endocrinol 2005;34:517-534.
112. Ryan IP, Schriock ED, Taylor RN: Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocrinol Metab 1994;78:642-649.
113. Ota H, Igarashi S, Sasaki M, Tanaka T: Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-566.
114. Wu MH, Sun HS, Lin CC, et al: Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod 2002;8:1103-1110.
115. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
116. Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82:434-448.
117. Gaetje R, Kotzian S, Herrmann G, et al: Invasiveness of endometriotic cells in vitro. Lancet 1995;346:1463-1464.
118. Zeitvogel A, Baumann R, Starzinski-Powitz A: Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 2001;159:1839-1852.
119. Arnold JT, Kaufman DG, Seppala M, Lessey BA: Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod 2001;16:836-845.
120. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-2468.
121. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419-424.
122. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
123. Wolf DM, Fuqua SA: Mechanisms of action of antiestrogens. Cancer Treat Rev 1995;21:247-271.
124. Fornander T, Rutqvist LE: Adjuvant tamoxifen and second cancers. Lancet 1989;1:616.
125. Mourits MJ, De Vries EG, Willemse PH, et al: Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97:855-866.
126. Pole JC, Gold LI, Orton T, et al: Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Toxicology 2005;206:91-109.
127. De Angelis CD, Drazen JM, Frizelle FA, et al: Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-1829.
128. Pritts EA, Zhao D, Ricke E, et al: PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002;87:1841-1844.
129. Pritts EA, Zhao D, Sohn SH, et al: Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 2003;80:415-420.
130. Lebovic DI, Kir M, Casey CL: Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82(suppl 3):1008-1013.
131. Demirturk F, Aytan H, Caliskan AC, et al: Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58-62.
132. Harris HA, Bruner-Tran KL, Zhang X, et al: A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20:936-941.
133. Stratton P, Hartog B, Hajizadeh N, et al: A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092-1099.
134. Passaro MD, Piquion J, Mullen N, et al: Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod 2003;18:1820-1827.
135. Drazen JM, Wood AJ: Trial registration report card. N Engl J Med 2005;353:2809-2811.
136. Petroski H, Success through Failure: The Paradox of Design. Princeton, Princeton University Press, 2006.
137. Guo SW: Nuclear factor-κB (NF-κB): An unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest 2007;63:71-97.